JATT II Acquisition Corp Ordinary Shares (JATT)
Key Financials
| Current Price | $10.29 |
| Market Cap | $80M |
| P/E Ratio | — |
| ROE | —% |
| Dividend Yield | 0% |
| Sector | Financial Services |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I look for a business with durable economics, honest accounting, and a sensible price. JATT II Acquisition Corp is still a blank-check shell, so there is no operating business to judge. The filed figures show no revenue, and in fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$68,793, while in fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$305,553. That is a small absolute loss, but it is still a loss and tells us nothing about future earning power. There is no competitive moat to speak of because there is no product, customer relationship, or cost advantage yet. Financial health is difficult to assess from the fragmentary data; the FairStock calculation shows D/E of 2.40, and the company has only two quarters of filed results. On valuation, at the 2026-10-16 close of $10.26, the market cap is $80.0M and FairStock's P/B calculation is 3125.00 — an extreme multiple against accounting book value. The stock has traded between $9.99 and $23.76 over the past 52 weeks, which suggests speculation rather than investment. Growth cannot be measured: revenue growth is N/A and there is no Lynch category because only 0 years of filed results are available, versus the 3 years needed. A SPAC can create value if it finds a high-quality healthcare business at a fair price, but I have no evidence of that yet. At $10.26, I would call it event-driven speculation, not a Graham-style bargain.
In plain English: This company is a shell company that plans to merge with a healthcare business. It has no revenue and reported small losses, so there is no real operating business to judge as strong or weak. At $10.26, the stock is near the low end of its 52-week range but very high compared with the tiny accounting value on its books, so the price does not look cheap based on its numbers.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-16 close · note generated 2026-10-20 · model deepseek-flash
Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31)
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer